Role of MUC1 in Pancreatic Cancer

MUC1 在胰腺癌中的作用

基本信息

  • 批准号:
    7700439
  • 负责人:
  • 金额:
    $ 21.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objective of the proposed study is to understand the oncogenic role of MUC1 glycoprotein in the development and progression of infiltrating ductal adenocarcinoma of the pancreas (PDA) from preinvasive neoplasias (PanlNs) to invasive adenocarcinomas, and to evaluate the efficacy of MUC1-targeted therapeutic intervention for the treatment and/or prevention of this devastating disease. MUC1 (CD227) is a membrane tethered mucin glycoprotein overexpressed and aberrantly glycosylated in >60% of human ductal pancreatic adenocarcinoma. Tumor-associated MUC1 is known to be associated with the metastatic phenotype of cancer cells. MUC1 is recently identified as a potential oncogene, and has been an active target for therapeutic intervention in several cancers including PDA. Over expression of MUC1 in PDA has long been known, but its function has been difficult to elucidate, partly due to the lack of appropriate models. With the advent of siRNA technology and the recent development of a mouse model of PDA, we can begin to fully elucidate the role of MUC1. Our hypothesis is that MUC1 plays an important oncogenic function in pancreatic cancer development and serves as a target for therapeutic intervention. Our specific aims are 1) To determine the functional role of MUC1 in human pancreatic cancer cell lines; 2) To determine the effects on the development of PanlNs and PDA in Mud -deficient PDA mice; and 3) To evaluate the effects on the development of PanlNs and PDA in PDA mice expressing human MUC1. These mouse models provide an unique and distinctive opportunity to not only understand the role of MUC1 during pancreatic cancer development, but also offers us the ability to evaluate MUC1-targeted immune therapy in the PDA mice that expresses human MUC1 as a self-antigen. In the third aim we also propose to determine novel strategies to reduce tumor-induced immune-suppression within the tumor microenvironment to improve efficacy of targeted immune therapy. This project is extremely relevant to pancreatic cancer. These preclinical studies will form the basis for designing more efficacious and novel therapies to combat the mortality associated with PDA.
描述(由申请人提供):本研究的目的是了解MUC 1糖蛋白在胰腺浸润性导管腺癌(PDA)从浸润前肿瘤(PanIN)发展和进展为浸润性腺癌中的致癌作用,并评价MUC 1靶向治疗干预治疗和/或预防这种毁灭性疾病的疗效。MUC 1(CD 227)是一种膜系粘蛋白糖蛋白,在>60%的人胰腺导管腺癌中过度表达和异常糖基化。已知肿瘤相关MUC 1与癌细胞的转移表型相关。MUC 1最近被鉴定为潜在的癌基因,并且已经成为包括PDA在内的多种癌症的治疗干预的活性靶点。MUC 1在PDA中的过度表达早已为人们所知,但其功能一直难以阐明,部分原因是缺乏合适的模型。随着siRNA技术的出现和最近PDA小鼠模型的发展,我们可以开始充分阐明MUC 1的作用。我们的假设是MUC 1在胰腺癌的发展中起着重要的致癌作用,并作为治疗干预的靶点。我们的具体目的是1)确定MUC 1在人胰腺癌细胞系中的功能作用; 2)确定对Mud缺陷型PDA小鼠中PanIN和PDA发育的影响;和3)评估对表达人MUC 1的PDA小鼠中PanIN和PDA发育的影响。这些小鼠模型提供了一个独特的机会,不仅了解MUC 1在胰腺癌发展过程中的作用,而且还为我们提供了在表达人MUC 1作为自身抗原的PDA小鼠中评估MUC 1靶向免疫治疗的能力。在第三个目标中,我们还提出确定新的策略来减少肿瘤微环境中肿瘤诱导的免疫抑制,以提高靶向免疫治疗的疗效。这个项目与胰腺癌非常相关。这些临床前研究将为设计更有效和新颖的治疗方法以对抗PDA相关的死亡率奠定基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pinku Mukherjee其他文献

Pinku Mukherjee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pinku Mukherjee', 18)}}的其他基金

An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer.
使用血清和成像生物标志物早期检测胰腺癌的综合策略。
  • 批准号:
    10325659
  • 财政年份:
    2021
  • 资助金额:
    $ 21.46万
  • 项目类别:
The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma
使用tMUC1/CD3双特异性抗体控制胰腺导管腺癌
  • 批准号:
    10325036
  • 财政年份:
    2021
  • 资助金额:
    $ 21.46万
  • 项目类别:
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site
P-4:将免疫调节疗法直接递送至胰腺肿瘤部位
  • 批准号:
    8719563
  • 财政年份:
    2013
  • 资助金额:
    $ 21.46万
  • 项目类别:
MUC1 regulation of TGF-beta function in pancreatic cancer cells
MUC1 对胰腺癌细胞中 TGF-β 功能的调节
  • 批准号:
    8445762
  • 财政年份:
    2013
  • 资助金额:
    $ 21.46万
  • 项目类别:
MUC1 regulation of TGF-beta function in pancreatic cancer cells
MUC1 对胰腺癌细胞中 TGF-β 功能的调节
  • 批准号:
    8598463
  • 财政年份:
    2013
  • 资助金额:
    $ 21.46万
  • 项目类别:
MUC1 enhances Neuropilin-1 signaling in pancreatic ductal adenocarcinoma
MUC1 增强胰腺导管腺癌中的 Neuropilin-1 信号传导
  • 批准号:
    8434641
  • 财政年份:
    2013
  • 资助金额:
    $ 21.46万
  • 项目类别:
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site
P-4:将免疫调节疗法直接递送至胰腺肿瘤部位
  • 批准号:
    7510798
  • 财政年份:
    2008
  • 资助金额:
    $ 21.46万
  • 项目类别:
Role of MUC1 in Pancreatic Cancer
MUC1 在胰腺癌中的作用
  • 批准号:
    7253970
  • 财政年份:
    2006
  • 资助金额:
    $ 21.46万
  • 项目类别:
Role of MUC1 in Pancreatic Cancer
MUC1 在胰腺癌中的作用
  • 批准号:
    7816655
  • 财政年份:
    2006
  • 资助金额:
    $ 21.46万
  • 项目类别:
Role of MUC1 in Pancreatic Cancer
MUC1 在胰腺癌中的作用
  • 批准号:
    7146300
  • 财政年份:
    2006
  • 资助金额:
    $ 21.46万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 21.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了